Saturday 17 October 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
262.03
5.90
−2.20%
Follow ILMN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
31.16% | 33.36% | 33.82% | 32.38% | |
Piotroski F-Score |
8 | 8 | 6 | 6 | |
| 11.52% | 13.13% | 13.39% | 12.95% | ||
ROIC |
23.22% | 19.55% | 17.69% | 17.46% | |
Return on Tangible Assets |
44.37% | 34.51% | 44.27% | 41.23% | |
Average Days of Receivables |
62.05 | 71.77 | 61.32 | 62.07 | |
Free Cash Flow per Share |
6.54 | 6.01 | 6.37 | 6.17 | |
Free Cash Flow |
1,000.00 | 931.00 | 974.00 | 931.00 | |
Capital Expenditures |
(122.00) | (148.00) | (154.00) | (164.00) | |
| Other line items | |||||
Cash ROIC |
21.49% | 15.93% | 18.30% | 16.94% | |
Accounts Receivable Turnover |
6.01 | 5.47 | 6.11 | 6.13 | |
Accounts Payable Turnover |
7.09 | 6.39 | 6.99 | 7.02 | |
Inventory Turnover |
2.49 | 2.65 | 2.59 | 2.51 | |
Average Days of Payables |
54.91 | 59.47 | 53.58 | 55.60 | |
Days of Inventory on Hand |
148.62 | 139.76 | 150.18 | 152.04 | |
Tax Rate |
(0.23) | (0.22) | (0.20) | (0.19) | |
Research and Development Expense of Revenue |
22.85% | 22.27% | 21.74% | 21.37% | |
Selling, General and Administrative Expense of Revenue |
24.37% | 25.01% | 24.83% | 25.15% | |
Share Based Compensation of Revenue |
6.79% | 6.33% | 5.96% | 5.92% | |
Interest Coverage |
7.71 | 7.99 | 8.52 | 8.92 | |
Operating CF/Net income |
1.60 | 1.27 | 1.32 | 1.33 | |
Depreciation/Fixed assets |
0.37 | 0.36 | 0.36 | 0.37 | |
Capex/Depreciation |
(0.44) | (0.55) | (0.57) | (0.60) | |
Revenue per Share |
28.03 | 28.02 | 28.71 | 29.76 | |
Operating CF per Share |
7.33 | 6.96 | 7.37 | 7.25 | |
Capex per Share |
(0.80) | (0.95) | (1.01) | (1.09) | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.04 |
Columns are period end dates